WHO Drug Information articles from September 2006

WHO Drug Information archives from September 2006

Emergence of extensively drug-resistant tuberculosis.(Medicines for Tuberculosis)
September 22, 2006... Tuberculosis (TB) is generally treated with a course of four first-line drugs. However, if misused or mismanaged, resistance can develop and multidrug-resistant TB has emerged as a serious threat to the success of treatment programmes....

WHO Global Task Force on XDR-TB launched.(Medicines for Tuberculosis)
September 22, 2006... At its first meeting in October 2006, a WHO Global Task Force outlined a series of measures that countries must implement to effectively combat XDR-TB. The Task Force has acted to establish teams that can respond to requests for technical...

Development of new drugs for tuberculosis.(Medicines for Tuberculosis)
September 22, 2006... An analysis of the current drug pipeline for tuberculosis drugs has been published in a recent report by Medecins sans Frontieres (MSF) * in support of its Campaign for Access to Essential Medicines. The analysis shows that greater investment...

Current drug pipeline for tuberculosis chemotherapy.(Medicines for Tuberculosis)
September 22, 2006... With approximately 9 million people developing active tuberculosis (TB) every year and 1.7 million deaths annually, TB is far from under control. Human immunodeficiency virus infection dramatically increases the risk of developing active...

Diarylquinoline TMC207 (Johnson & Johnson).(Novel chemical entities)(Brief article)
September 22, 2006... Diarylquinoline TMC207 is a promising member of a new class of anti-mycobacterial agents. The target and mechanism of action is different from those of other anti-TB agents implying low probability of cross-resistance with existing TB drugs....

Nitroimidazole PA-824 (Chiton Corp.-TB Alliance).(Novel chemical entities)
September 22, 2006... Nitroimidazole PA-824 is a new nitroimidazole derivative currently being developed by the TB Alliance. After activation by a mechanism dependent on M. tuberculosis F420 factor, PA-824 acts mainly by inhibiting the synthesis of cell wall...

Nitroimidazole OPC-67683 (Otsuka Pharmaceuticals, Japan).(Novel chemical entities)
September 22, 2006... Little information about this compound is publicly available. It belongs to a subclass of mycolic acid inhibitors. In vitro, OPC-67683 showed high activity against drug-sensitive as well drug-resistant strains. No cross-resistance with any of...

Pyrrole LL- 3858 (Lupin Limited, India).(Novel chemical entities)(Brief article)
September 22, 2006... Very limited information on the development of pyrroles as antimycobacterial agents is currently available. Pyrrole derivatives were found to be active against standard and drug-sensitive M. tuberculosis strains in vitro. Pyrrole derivative...

Pleuromutilins (GlaxoSmithKline--TB Alliance Partnership.(Novel chemical entities)(Brief article)
September 22, 2006... The pleuromutilins represent a novel class of antibiotics derived from a natural product. They interfere with protein synthesis by binding to the 23S rRNA. Despite the novelty of this class of compounds, recent studies have shown that...

Dipiperidine SQ-609 (Sequella Inc.).(Novel chemical entities)
September 22, 2006... Dipiperidine SQ-609 is a novel compound structurally unrelated to existing anti-TB drugs. It kills M. tuberculosis by interfering with cell wall biosynthesis (precise mechanism unknown). Antimicrobial activity has been demonstrated in vivo in...

ATP Synthase Inhibitor FAS20013 (FASgene).(Novel chemical entities)(Brief article)
September 22, 2006... FAS20013 is a novel compound belonging to the class of [beta]-sulphonylcarboxamides. The compound is very effective in killing MDR-TB organisms that are resistant to multiple drugs currently in use. A series of recent laboratory experiments...

Translocase I Inhibitor (Sequella Inc.).(Novel chemical entities)
September 22, 2006... Translocase inhibitors specifically inhibit mycobacterial translocase I, an enzyme required for bacterial cell wall synthesis. Preclinical evaluation of the compounds is planned.

InhA Inhibitors (GlaxoSmithKline-TB Alliance).(Novel chemical entities)
September 22, 2006... InhA, the enoyl reductase enzyme from M. tuberculosis catalyses the last step in the fatty acid biosynthesis pathway (FAS II). Frontline anti-tuberculosis drugs such as isoniazid (INH) target this enzyme. Drug resistance to INH results...

Isocitrate Lyase Inhibitors (GlaxoSmithKline--TB Alliance).(Novel chemical entities)(Brief article)
September 22, 2006... The isocitrate lyase (ICL) enzyme has been shown to be essential for long-term persistence of M. tuberculosis in mice, but not required for bacilli viability in normal culture or hypoxic conditions. Inhibition of the two isoforms of isocytrate...

Compounds originating from existing families of drugs.(Medicines for Tuberculosis)
September 22, 2006... Other promising candidate anti-TB drugs include: Gatifloxacin, Moxifloxacin, Diamine SQ-109, Non-Fluorinated Quinolones, Nitrofuranylamides, Picolinamide Imidazoles, Thiolactomycin Analogs, Dihydrolipoamide Acyltrans ferase Inhibitors,...

Timeline for development of candidate drugs.(Medicines for Tuberculosis)(Chronology)
September 22, 2006... Clinical trials to register a TB drug represent a lengthy and expensive process that can take a minimum of six years, generally longer than for other infectious diseases. The greatest challenge in the design of TB clinical trials is in Phase...

Teratogenicity of antiepileptic drugs.(Safety and Efficacy Issues)
September 22, 2006... Prescribing for women with epilepsy is complicated by the potential teratogenicity of antiepileptic drugs. Current guidelines recommend that the most effective drug should be chosen before conception and prescribed at its lowest effective dose,...

Meningococcal vaccine and Guillain Barre syndrome.(Safety and Efficacy Issues)
September 22, 2006... United States of America -- The Food and Drug Administration (FDA) and Centers for disease Control (CDC) have updated an October 2005 alert to consumers and health care providers regarding reports of Guillain Barre syndrome (GBS) following...

Panama mystery illness traced to diethylene] glycol.(Safety and Efficacy Issues)
September 22, 2006... Panama -- Reports have been received of another incident of diethylene glycol (DEG) poisoning, this time in Panama. By 29 October 2006, a total of 82 persons--including 35 hospitalized and 38 fatal cases--had been affected by acute renal...

Imatinib and cardiac dysfunction.(Safety and Efficacy Issues)
September 22, 2006... Canada -- Recent safety reports have been received on significant left ventricular ejection fraction reduction or congestive heart failure and use of imatinib mesylate (Gleevac[R]). Imatinib mesylate is indicated for the treatment of adult...

Online reporting of adverse reactions.(Safety and Efficacy Issues)(Brief article)
September 22, 2006... Canada -- Health Canada's MedEffect Web site has been updated to accept online transmittable reports of suspected adverse reactions (ARs) to health products marketed in Canada. Now, in addition to the previous reporting methods, health care...

SSRI-tricyclic antidepressant interaction.(Safety and Efficacy Issues)
September 22, 2006... New Zealand -- Prescribers are reminded of the potential for interactions to occur when a selective serotonin reuptake inhibitor (SSRI) antidepressant is co-prescribed with a tricyclic antidepressant (TCA). Concurrent use of SSRIs can elevate...

Telithromycin: hepatic events and myasthenia gravis.(Safety and Efficacy Issues)
September 22, 2006... Canada -- Based on information in published case reports and post-market adverse event reports, the Canadian Product Monograph for telithromycin (Ketek[R]) has been revised to include information on severe and sometimes fatal hepatotoxicity and...

BioGlue[R]: chronic inflammation.(Safety and Efficacy Issues)
September 22, 2006... Canada -- BioGlue[R] is the commercial name of a surgical adhesive composed of bovine serum albumin (BSA) and glutaraldehyde (1). The glutaraldehyde molecules covalently bond the BSA molecules to each other and, upon application, to tissue...

Beware the triple whammy!(Safety and Efficacy Issues)
September 22, 2006... Australia -- The Australian Adverse Drug Reactions Committee (ADRAC) has previously warned prescribers about the 'triple whammy'--a combination of an ACE inhibitor (ACEI) or an angiotensin II receptor antagonist (A2RA), a diuretic and an NSAID...

Colchicine: safe use is critical.(Safety and Efficacy Issues)
September 22, 2006... New Zealand -- Colchicine in overdose is extremely toxic and has resulted in fatalities. Prescribers are reminded that colchicine is now indicated as second-line therapy in the treatment of acute gout, after nonsteroidal anti-inflammatory...

Nitrofurantoin: monitor lung function in long-term use.(Safety and Efficacy Issues)
September 22, 2006... New Zealand -- An earlier article in Prescriber Update reported a case of fatal interstitial lung disease resulting from long-term nitrofurantoin therapy (1). The Centre for Adverse Reactions Monitoring continues to receive reports of acute and...

Proton pump inhibitors and interstitial nephritis.(Safety and Efficacy Issues)
September 22, 2006... New Zealand -- Acute renal impairment caused by interstitial nephritis is a recognized complication of treatment with omeprazole. Presenting symptoms may be non-specific and include malaise, fever, nausea, lethargy, weight loss, rash and...

Package insert changes.(Safety and Efficacy Issues)
September 22, 2006... Singapore -- The Health Sciences Agency (HSA) has approved the following package insert changes in accordance with safety updates from January to March 2006. 1. Calcitriol (Calcijex[R], Abbott) Under "Precautions", it is stated that...

Leflunomide and peripheral neuropathy.(Safety and Efficacy Issues)
September 22, 2006... Australia -- Leflunomide is a disease modifying anti-rheumatic prodrug (DMARD) with immunosuppressive properties. It has been available in Australia since 2000 for the treatment of active rheumatoid arthritis. To date, ADRAC has received...

Ezetimibe and depression?(Safety and Efficacy Issues)
September 22, 2006... Australia -- Ezetimibe (Ezetrol[R]) was registered in Australia in June 2003 for treatment of hypercholesterolaemia. Since then, ADRAC has received 265 reports of suspected adverse reactions associated with the use of this drug. Twelve of the...

Sirolimus: acute rejection in renal transplant patients.(Safety and Efficacy Issues)
September 22, 2006... Canada -- Increased risk of rejection in de novo renal transplant patients receiving sirolimus (Rapamune[R]), mycophenolate mofetil, and corticosteroid, used in combination with interleukin-2 receptor antibody induction have been reported in an...

Safety update for oseltamivir.(Safety and Efficacy Issues)(Clinical report)
September 22, 2006... United States of America -- The manufacturer of oseltamivir phosphate (Tamiflu[R]) has advised health professionals of a recent revision to the product label as a result of adverse events reported during postmarketing clinical use. Oseltamivir...

Darifenacin hydrobromide for overactive bladder: what clinical advantage?(Safety and Efficacy Issues)(Drug overview)
September 22, 2006... Australia -- Darifenacin hydrobromide (Enablex[R]) 7.5 mg and 15 mg prolonged-release tablets have been approved ifor overactive bladder. The contraction of detrusor smooth muscle involves stimulation of muscarinic receptors by...

Tigecycline for serious infections.(Safety and Efficacy Issues)
September 22, 2006... Australia -- Tigecycline (Tygacil[R]) vials containing 50 mg lyophilised powder for reconstitution have been approved for complicated skin and soft tissue infections and complicated intra-abdominal infections. Tigecycline is structurally...

The role of prescribed and defined daily doses in pharmacoepidemiology.(Rational Use of Medicines)(Brief article)
September 22, 2006... In pharmacoepidemiological studies, it is important to use one single measurement for the volume of drugs prescribed, dispensed or consumed. For many years, the defined daily dose (DDD) has been the globally accepted standard unit for such...

Asthma/COPD drugs: PDDs are critical to determining DDDs.(Rational Use of Medicines)
September 22, 2006... The present study * was conducted with the aim of improving the rational use of medicines through application of DDDs and PDDs to data available concerning the treatment of asthma and COPD in Sweden. DDDs for different drug substances are...

Development of medicines for neonates.(Topics of Current Interest)
September 22, 2006... The development of safe and effective medicines for newborn babies requires stronger cooperation between researchers, developers and regulators. This was one of the main conclusions of a workshop, organized by the European Medicines Agency...

Plan for paediatric essential medicines.(Topics of Current Interest)
September 22, 2006... With millions of children dying every year from treatable diseases, United Nations agencies have devised a plan aimed at increasing children's access to essential medications. WHO and UNICEF held a joint meeting in Geneva in August 2006 to form...

200 African scientists join forces.(Topics of Current Interest)
September 22, 2006... Over 200 African scientists from 23 countries met in September 2006 at an international conference to engender greater regional research partnership to combat the most neglected diseases such as sleeping sickness, kala azar and malaria. Since...

New strategy to fight tropical diseases.(Topics of Current Interest)(Brief article)
September 22, 2006... WHO and a group of more than 25 partner organizations has unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people by combining treatment regimens for different diseases, but...

ICH efforts to improve processes.(Topics of Current Interest)(International Conference on Harmonization)
September 22, 2006... The International Conference on Harmonization (ICH) Steering Committee and its expert working groups met in Chicago, USA, from 21-26 October 2006. ICH aims to collaborate with accredited Standards Development Organizations to leverage the...

Anticounterfeiting Taskforce develops strategy.(Topics of Current Interest)
September 22, 2006... The World Health Organization (WHO) and its partners have officially launched the International Medical Products Anti-counterfeiting Taskforce (IMPACT) at a meeting in Germany on 15 November 2006. IMPACT is made up of WHO Member States and more...

According to the head of the National Department of Intellectual Copyright Crime of the Economic Police.(Angola)
September 22, 2006... According to the head of the National Department of Intellectual Copyright Crime of the Economic Police, approximately 70% of medicines used by the population may be forgeries.

A Cambodian Health Ministry survey conducted in 2002 revealed that 13% of drugs on the domestic market were counterfeit or substandard.(Cambodia)
September 22, 2006... A Cambodian Health Ministry survey conducted in 2002 revealed that 13% of drugs on the domestic market were counterfeit or substandard, especially antimalarial drugs and antibiotics.

China's Research and Development-based Pharmaceutical Association estimates that about 8% of over-the-counter drugs sold in China.(China)
September 22, 2006... China's Research and Development-based Pharmaceutical Association estimates that about 8% of over-the-counter drugs sold in China are counterfeit.

According to the Association of Colombian Pharmaceutical Industries (ASINFAR), it is estimated that out of a total US$1300 million in annual medicines sales.(Colombia)
September 22, 2006... According to the Association of Colombian Pharmaceutical Industries (ASINFAR), it is estimated that out of a total US$1300 million in annual medicines sales, almost 5 percent stem from contraband, counterfeiting or adulteration.

The Public Health Department has reported that 50% of pharmacies operate illegally and that, according to statistics, 10% of the medicines that arrive in the country are fake.(Dominican Republic)
September 22, 2006... The Public Health Department has reported that 50% of pharmacies operate illegally and that, according to statistics, 10% of the medicines that arrive in the country are fake. Some of the medicines found had expired over 10 years ago!

INQUIFAR, the Association of Pharmaceutical Companies, has denounced the widespread availability of counterfeit drugs on the domestic market.(El Salvador)
September 22, 2006... INQUIFAR, the Association of Pharmaceutical Companies, has denounced the widespread availability of counterfeit drugs on the domestic market. According to a local drug manfacturer, the commercialization of counterfeit medicines currently causes...

Indian pharmaceutical companies have suggested that in major cities, one in five strips of medicines sold is fake.(India)
September 22, 2006... Indian pharmaceutical companies have suggested that in major cities, one in five strips of medicines sold is fake. They claim a loss in revenue of between 4% and 5% annually. The industry also estimates that spurious drugs have grown from 10 to...

The International Pharmaceutical Manufacturers Group (IPMG) in Indonesia has estimated that pirated drugs constitute 25% of Indonesia's US$2 billion pharmaceutical market.(Indonesia)
September 22, 2006... The International Pharmaceutical Manufacturers Group (IPMG) in Indonesia has estimated that pirated drugs constitute 25% of Indonesia's US$2 billion pharmaceutical market. According to IPMG, fake drugs hit foreign pharmaceutical companies'...

A random survey by the National Quality Control Laboratory (NQCL) and the Pharmacy and Poisons Board found the almost 30% of drugs in Kenya are counterfeit.(Kenya)
September 22, 2006... A random survey by the National Quality Control Laboratory (NQCL) and the Pharmacy and Poisons Board found the almost 30% of drugs in Kenya are counterfeit. Some of the drugs have been described as no more than just chalk and water being...

The chief of Lebanon's National Health Commission (NHC).(Lebanon)
September 22, 2006... The chief of Lebanon's National Health Commission (NHC), has estimated that 35% of pharmaceuticals available in the Lebanese market are counterfeit products.

During 2004, federal agents seized--in two regions--approximately 60 tons of stolen, expired and counterfeit pharmaceuticals.(Mexico)
September 22, 2006... During 2004, federal agents seized--in two regions--approximately 60 tons of stolen, expired and counterfeit pharmaceuticals. There is concern in the pharmaceutical industry at the rapid growth in sales of counterfeit and contraband products....

The National Agency for Food, Drug Administration and Control (NAFDAC) announced that the prevalence of counterfeit drugs has dropped to 16%.(Nigeria)
September 22, 2006... The National Agency for Food, Drug Administration and Control (NAFDAC) announced that the prevalence of counterfeit drugs has dropped to 16% at the beginning of 2006.

Some US$66 million of counterfeit and adulterated pharmaceuticals are sold in Peru every year.(Peru)
September 22, 2006... Some US$66 million of counterfeit and adulterated pharmaceuticals are sold in Peru every year. In the capital alone, there are 1800 stores devoted to this illegal business. The General Directorate of Medicines, Supplies and Drugs (DIGEMID) of...

The Association of Pharmaceutical Laboratories of Peru (ALAFARPE) estimates that the illegal pharmaceuticals trade in the country represents around US$ 40 million.(Peru)
September 22, 2006... The Association of Pharmaceutical Laboratories of Peru (ALAFARPE) estimates that the illegal pharmaceuticals trade in the country represents around US$ 40 million. This figure includes medicines that enter the country as contraband, are...

Around 200 pharmacies operate in downtown Lima with neither registration nor authorization issued by the Ministry of Health.(Peru)
September 22, 2006... Around 200 pharmacies operate in downtown Lima with neither registration nor authorization issued by the Ministry of Health. According to the Municipal Health Department, they sell 40% contraband pharmaceuticals and 12% adulterated or expired...

In 2003, the former director of the Bureau of Food and Drug (BFAD), has estimated that 30% of drug store outlets visited by food and drug deregulation officers.(Philippines)
September 22, 2006... In 2003, the former director of the Bureau of Food and Drug (BFAD), has estimated that 30% of drug store outlets visited by food and drug deregulation officers carry and sell counterfeit drugs.

The Federal Service for Health Sphere Supervision (FSHSS) reported that 10% of all drugs on the Russian market were counterfeit.(Russia)
September 22, 2006... The Federal Service for Health Sphere Supervision (FSHSS) reported that 10% of all drugs on the Russian market were counterfeit. However, other sources estimate that the real figure could be much higher.

Bevacizumab approved for lung cancer.(Regulatory Action and News)
September 22, 2006... United States of America -- The Food and Drug Administration (FDA) has approved use of bevacizumab (Avastin[R]) in combination with carboplatin and paclitaxel for initial systemic treatment of patients with unresectable, locally advanced,...

Risperidone for irritability associated with autism.(Regulatory Action and News)
September 22, 2006... United States of America -- The Food and Drug Administration (FDA) has approved risperidone (Risperdal[R]) orally disintegrating tablets, an adult antipsy chotic drug, for the symptomatic treatment of irritability in autistic children and...

New treatment for chronic hepatitis B.(Regulatory Action and News)
September 22, 2006... United States of America -- The Food and Drug Administration (FDA) has approved telbivudine (Tyzeka[R]) for the treatment of adults with chronic hepatitis B (HBV), a serious viral infection that can cause lifelong infection, scarring of the...

Influenza virus vaccine composition: 2007 southern hemisphere.(Regulatory Action and News)
September 22, 2006... World Health Organization--It is recommended that vaccines to be used in the 2007 season (southern hemisphere Winter) contain the following: * an A/New Caledonia/20/99(H1N1)-like virus; * an A/Wisconsin/67/2005(H3N2)-like virus (The...

Sitagliptin phosphate for diabetes.(Regulatory Action and News)
September 22, 2006... United States of America -- The Food and Drug Administration (FDA) has approved sitagliptin phosphate (Januvia[R]), the first diabetes treatment in a new class of drugs known as DPP-4 inhibitors that enhances the body's own ability to lower...

Dronedarone marketing application withdrawn.(Regulatory Action and News)
September 22, 2006... European Union--The European Medicines Agency (EMEA) has been formally notified by manufacturer of the decision to withdraw the application for a centralized marketing authorisation for the medicinal product dronedarone hydrochloride...

Repaglinide marketing authorization extension request withdrawn.(Regulatory Action and News)
September 22, 2006... European Union--The manufacturer of repaglinide (NovoNorm[R] and Prandin[R]) 0.5 mg, 1 mg and 2 mg tablets has notified the European Medicines Agency (EMEA) of its decision to withdraw the application for an extension of the marketing...

Abetimus marketing authorization request withdrawn.(Regulatory Action and News)
September 22, 2006... European Union--The manufacturer of abetimus sodium (Riquent[R]) has notified the European Medicines Agency (EMEA) of its decision to withdraw an application for a centralized marketing authorization. Abetimus sodium was designated as an orphan...

Imatinib mesilate: revised indications.(Regulatory Action and News)
September 22, 2006... European Union--The manufacturer of imatinib mesilate (Glivec[R]), 50 mg and 100 mg capsules and 100 mg and 400 mg film-coated tablets, has notified the European Medicines Agency (EMEA) of its decision to withdraw the application for a change...

Vigiflow Online for pharmacovigilance.(Recent Publications, Information and Events)(Brief article)
September 22, 2006... The validation of Vigiflow case report management system has now been completed and version 3.0 was successfully released in February 2006. The Vigiflow web-based software allows seamless electronic transmission of adverse drug reaction...

Scientific plant names and synonyms.(Recent Publications, Information and Events)
September 22, 2006... The Uppsala Monitoring Centre's work on herbal synonyms in the form of lists of accepted scientific names and their latin and vernacular synonyms has now been published. Reference: The Uppsala Monitoring Centre. http://www.who-umc.org

Pharmaceutical inventory control software.(Recent Publications, Information and Events)
September 22, 2006... The latest release of mSupply v1.94 pharmaceutical inventory control software has been announced. New features include: * a French version under construction. * better PDF generation support * support for direct printing to label...

Reporting adverse reactions and continuing education.(Recent Publications, Information and Events)
September 22, 2006... In collaboration with the Canadian Medical Association (CMA), Health Canada has developed a continuing medical education (CME) course entitled Physician Reporting of Adverse (Drug) Reactions. A number of reference resources are available via...

Good governance in medicines procurement.(Recent Publications, Information and Events)
September 22, 2006... Huge amounts of money are spent every year on pharmaceutical products; a market so large that it is extremely vulnerable to corruption. The World Health Organization (WHO) has launched a new initiative to assist governments to promote greater...

WHO public hearings on innovation and intellectual property.(Recent Publications, Information and Events)
September 22, 2006... All parties with an interest in the upcoming Intergovernmental Working Group on Public Health, Innovation and Intellectual Property have been invited to present their views to a web-based public hearing organized by the World Health...

Pharmaceutical Forum: better information, access and prices.(Recent Publications, Information and Events)
September 22, 2006... The European Commission has set up the Pharmaceutical Forum to find practical solutions to some of the key structural and public health issues affecting the pharmaceutical industry. The Pharmaceutical Forum brings together Member States, the...

Pharmacy education symposium: multidisciplinary practice.(Recent Publications, Information and Events)
September 22, 2006... Registration is now open for the Fourth Pharmacy Education Symposium: Teaching for multidisciplinary practice to be held in Italy in July 2007. Programme summary Day 1 : Teaching and learning in a traditional environment. Day 2:...

Pharmaceutical policy analysis conference in 2007.(Recent Publications, Information and Events)
September 22, 2006... A conference on pharmaceutical policy analysis, including sociocultural, economic, regulatory and epidemiological aspects of pharmaceuticals and international health will be held from 19-21 September 2007, in Zeist, Netherlands. Everybody who...

Final guidance on quality systems.(Recent Publications, Information and Events)(Brief article)
September 22, 2006... The US Food and Drug Administration (FDA) has released the final version of their Guidance for industry: quality systems approach to pharmaceutical CGMP regulations. This version finalizes the draft which was published in October 2004. The...

Newly available guidance documents.(Recent Publications, Information and Events)
September 22, 2006... The following guidance documents are now available on the US Food and Drug Administration website: * Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of...

International Nonproprietary Names for Pharmaceutical Substances (INN).
September 22, 2006... Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under...